Please login to the form below

Not currently logged in


This page shows the latest Karyopharm news and features for those working in and with pharma, biotech and healthcare.

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in milestone payments.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (, a trusted independent medical education website. Support...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...